Endocrine-Related Cancer
短名 | Endocr Relat Cancer |
Journal Impact | 4.03 |
国际分区 | ONCOLOGY(Q2) |
期刊索引 | SCI Q2中科院 2 区 |
ISSN | 1351-0088, 1479-6821 |
h-index | 146 |
国内分区 | 医学(2区)医学内分泌学与代谢(3区)医学肿瘤学(3区) |
ENDOCRINE-RELATED CANCER 是内分泌学会的官方旗舰期刊,得到欧洲内分泌学会、英国和爱尔兰神经内分泌学会以及日本激素和癌症学会的认可。内分泌相关癌症为发表高质量原创文章提供了一个独特的国际论坛,这些文章描述了新的、前沿的基础实验室、人类健康和疾病的转化和临床研究,重点是内分泌肿瘤和激素依赖性癌症;并用于发表这些主题的权威评论文章。内分泌肿瘤包括肾上腺皮质、乳腺、多发性内分泌肿瘤、神经内分泌肿瘤、卵巢、前列腺、副神经节瘤、甲状旁腺、垂体嗜铬细胞瘤、睾丸、甲状腺和激素依赖性癌症。还考虑了影响新陈代谢和能量产生的肿瘤,例如膀胱、骨骼、肾脏、肺和头颈部。
期刊主页投稿网址涉及主题 | 生物医学内科学遗传学化学生物化学癌症内分泌学癌症研究病理基因肿瘤科细胞生物学乳腺癌激素外科 |
出版信息 | 出版商: BioScientifica Ltd.,出版周期: Quarterly,期刊类型: journal |
基本数据 | 创刊年份: 1994,原创研究文献占比: 80.82%,自引率:2.40%, Gold OA占比: 17.48% |
平均审稿周期 | 网友分享经验:较慢,6-12周 |
平均录用比例 | 网友分享经验:一般 |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
2024-9-1
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple negative breast cancer patients
2024-9-1
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center
2024-8-1
Promoter mutation-independent TERT expression is related to immune-enriched milieu in papillary thyroid cancer
2024-8-1
SDHA related phaeochromocytoma and paraganglioma: review and clinical management
2024-8-1
Endocrine cancer trends 1990–2021: global disparities and health inequalities
2024-8-1
Nutrition, GH/IGF-I signaling, and cancer
2024-8-1
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature
2024-8-1
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy
2024-8-1
Thyroid dysfunction caused by immune-checkpoint-inhibitors improves cancer outcomes
2024-7-1
Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma
2024-7-1
Ectopic adrenocorticotropic hormone syndrome in patients with olfactory neuroblastoma
2024-7-1
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma
2024-7-1
Insights on Epidemiology, Morbidity and Mortality of Cushing’s Disease in Northern Ireland
2024-6-18
Genetic variants and down-regulation of CACNA1H in pheochromocytoma
2024-6-12
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
2024-6-3
Disease relapse in relation to lymph node sampling in lung carcinoid patients
2024-6-1
AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes
2024-6-1
Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study
2024-6-1
Changes in categorization or nomenclature within Neuroendocrine Tumours
2024-5-22
EPAS-1-related pheochromocytoma/paraganglioma: How common and how aggressive?
2024-5-20
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis
2024-5-20
Advancements and Challenges in Pheochromocytoma and Paraganglioma Research: A Collection of Insights
2024-5-17
Genotype-specific development of MEN 2 constituent components in 683 RET carriers
2024-5-16
Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
2024-5-7
Glucagon and insulin: 100 years young
2024-4-16
Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer
2024-4-1
GPNMB promotes tumor growth and is a biomarker for lymphangioleiomyomatosis
2024-4-1
Neuropilin-2 and soluble neuropilin-2 in neuroendocrine neoplasms
2024-4-1
Patient reported burden associated with pheochromocytoma/paraganglioma diagnosis
2024-4-1
A zebrafish xenotransplant model of anaplastic thyroid cancer to study the tumor microenvironment and innate immune cell interactions in vivo
2024-4-1
Genetic disorders and insulinoma/glucagonoma
2024-3-28
HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs
2024-3-8
Clinical and basic research implications of the article ‘IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer’
2024-3-5
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas
2024-3-1
RAB5A polarizes macrophage and promotes breast cancer
2024-3-1
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma
2024-2-16
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy
2024-2-8
Bioengineered in vitro three-dimensional tumor models in endocrine cancers
2024-2-2
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the United States, 2000–2020: a population-based retrospective cohort study
2024-2-1
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
2024-1-23
Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms
2024-1-22
Immunotherapy for endocrine tumours: a clinician’s perspective
2024-1-18
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma
2024-1-15
Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma
2024-1-12
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms
2024-1-12
Growth hormone and radiation therapy: friend, foe, or both?
2024-1-4
Sexual dimorphism in medullary thyroid cancer aggressiveness
2024-1-4
Acknowledgement to reviewers
2024-1-1
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?
2024-1-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远